Tumor heterogeneity and therapy resistance - implications for future treatments of prostate cancer

Abstract

Aim: To develop new therapies for prostate cancer, disease heterogeneity must be addressed. This includes patient variation, multi-focal disease, cellular heterogeneity, genomic changes and epigenetic modification. This requires more representative models to be used in more innovative ways.

Methods: This study used a panel of cell lines and primary prostate epithelial cell cultures derived from patient tissue. Several assays were used; alamar blue, colony forming assays, γH2AX and Ki67 immunofluorescence and comet assays. Ptychographic quantitative phase imaging (QPI), a label-free imaging technique, combined with Cell Analysis Toolbox software, was implemented to carry out real-time analysis of cells and to retrieve morphological, kinetic and population data.

Results: A combination of radiation and Vorinostat may be more effective than radiation alone. Primary prostate cancer stem-like cells are more resistant to etoposide than more differentiated cells. Analysis of QPI images showed that cell lines and primary cells differ in their size, motility and proliferation rate. A QPI signature was developed in order to identify two subpopulations of cells within a heterogeneous primary culture.

Conclusion: Use of primary prostate epithelial cultures allows assessment of therapies whilst taking into account cellular heterogeneity. Analysis of rare cell populations and embracing novel techniques may ultimately lead to identifying and overcoming treatment resistance.

Keywords

Prostate / ptychography / live-cell imaging / primary cells / quantitative phase imaging

References

[1] El-Amm J.The changing landscape in the treatment of metastatic castration-resistant prostate cancer..Ther Adv Med Oncol2013;5:25-40 PMCID:PMC3539272

[2] Hwang C.Overcoming docetaxel resistance in prostate cancer: a perspective review..Ther Adv Med Oncol2012;4:329-40 PMCID:PMC3481557

[3] Barbieri CE,Rubin MA.Molecular genetics of prostate cancer: emerging appreciation of genetic complexity..Histopathology2012;60:187-98

[4] Boutros PC,Harding NJ,Trudel D,Meng A,McPherson A,Zia A,Livingstone J,Wang J,Have CL,Sam M,Timms L,Wong A,Simmons TT,Zafarana G,Luo X,Prokopec SD,Dal Pra A,Brown A,Yousif F,Chong LC,Jung E,Starmans MH,Govind SK,D'Costa A,Waggott D,Lambin P,Cooper C,Neal D,Sahinalp C,Fleshner N,Collins CC,McPherson JD,Bristow RG.Spatial genomic heterogeneity within localized, multifocal prostate cancer..Nat Genet2015;47:736-45

[5] Fraser M,Bristow RG.Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer..Urol Oncol2015;33:85-94

[6] Wei L,Lampert E,DePriest AD,Gomez EC,Glenn ST,Morrison C,Mohler JL,Heemers HV.Intratumoral and intertumoral genomic heterogeneity of multifocal localized prostate cancer impacts molecular classifications and genomic prognosticators..Eur Urol2017;71:183-92

[7] Beltran H,Frampton GM,Downing SR,Jarosz M,Tagawa ST,Stephens PJ,Cronin MT.Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity..Eur Urol2013;63:920-6 PMCID:PMC3615043

[8] Baca SC,Lawrence MS,Romanel A,Park K,MacDonald TY,Van Allen E,Sboner A,Soong TD,Auclair D,Beltran H,Boysen G,Barbieri CE,Sivachenko A,Saksena G,Ramos AH,Cipicchio M,Kantoff PW,Gabriel SB,Meyerson M,Elemento O,Demichelis F,Garraway LA.Punctuated evolution of prostate cancer genomes..Cell2013;153:666-77 PMCID:PMC3690918

[9] Cooper CS,Wedge DC,Gundem G,Kremeyer B,Lynch AG,Massie CE,Luxton HJ,Kote-Jarai Z,Merson S,Zamora J,Thomas S,Ramakrishna M,Matthews L,Hurst R,Bristow RG,Fraser M,Raine K,Menzies A,Hinton J,McLaren S,Hardy C,Joseph O,Robinson B,Gamble S,Berney D,Livni N,Fisher C,Kumar P,Woodhouse C,Mayer E,Shah NC,Voet T,Futreal A,Warren AY,Stratton MR,McDermott U,Neal DE.Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue..Nat Genet2015;47:367-72 PMCID:PMC4380509

[10] Gundem G,Kremeyer B,Tubio JM,Brewer DS,Hognas G,Kivinummi K,Latimer C,Dawson KJ,Emmert-Buck MR,Foster C,Easton D,Group IPU,Cooper CS,Visakorpi T,McDermott U,Bova GS.The evolutionary history of lethal metastatic prostate cancer..Nature2015;520:353-7 PMCID:PMC4413032

[11] Hayward SW,Cunha GR,Deshpande N.Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1..In Vitro Cell Dev Biol Anim1995;31:14-24

[12] Maitland NJ,Hall J,Quinn G.In vitro models to study cellular differentiation and function in human prostate cancers..Radiat Res2001;155:133-42

[13] Frame FM,Collins AT.Harvesting human prostate tissue material and culturing primary prostate epithelial cells..Methods Mol Biol2016;1443:181-201

[14] Collins AT,Maitland NJ.Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression..J Cell Sci2001;114:3865-72

[15] Frame FM,Collins AT,Mann VM,Meuth M,Maitland NJ.HDAC inhibitor confers radiosensitivity to prostate stem-like cells..Br J Cancer2013;109:3023-33 PMCID:PMC3859953

[16] Sturmey RG,Barker EA.DNA damage and metabolic activity in the preimplantation embryo..Hum Reprod2009;24:81-91

[17] Kasprowicz R,O'Toole P.Characterising live cell behaviour: traditional label-free and quantitative phase imaging approaches..Int J Biochem Cell Biol2017;84:89-95

[18] Marrison J,Marriott P.Ptychography -- a label free, high-contrast imaging technique for live cells using quantitative phase information..Sci Rep2013;3:2369 PMCID:PMC3734479

[19] Suman R,Hazel KE,Coles M,Chawla S.Label-free imaging to study phenotypic behavioural traits of cells in complex co-cultures..Sci Rep2016;6:22032 PMCID:PMC4768090

[20] Frame FM,Bryden F,Mann VM,Boyle RW.Mechanisms of growth inhibition of primary prostate epithelial cells following gamma irradiation or photodynamic therapy include senescence, necrosis, and autophagy, but not apoptosis..Cancer Med2016;5:61-73 PMCID:PMC4708897

[21] Yan J.Prostate cancer stem-like cells proliferate slowly and resist etoposide-induced cytotoxicity via enhancing DNA damage response..Exp Cell Res2014;328:132-42

[22] Risbridger GP.Patient-derived prostate cancer: from basic science to the clinic..Horm Cancer2016;7:236-40

[23] Collins AT,Hyde C,Maitland NJ.Prospective identification of tumorigenic prostate cancer stem cells..Cancer Res2005;65:10946-51

[24] Sobel RE.Cell lines used in prostate cancer research: a compendium of old and new lines -- part 2..J Urol2005;173:360-72

[25] Sobel RE.Cell lines used in prostate cancer research: a compendium of old and new lines -- part 1..J Urol2005;173:342-59

[26] Ulukaya E,Cevatemre B,Walker H,Simms MS,Yilmaz VT.Differential cytotoxic activity of a novel palladium-based compound on prostate cell lines, primary prostate epithelial cells and prostate stem cells..PLoS One2013;8:e64278 PMCID:PMC3651166

[27] Hirst AM,Mann VM,O'Connell D.Low-temperature plasma treatment induces DNA damage leading to necrotic cell death in primary prostate epithelial cells..Br J Cancer2015;112:1536-45 PMCID:PMC4454887

[28] Butler DE,Walker HF,Mann VM,Davies BR,Maitland NJ.Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer..Oncotarget2017;8:56698-713

[29] Pellacani D,Droop AP,Berry PA,Stower MJ,Mann VM,Risbridger GP.DNA hypermethylation in prostate cancer is a consequence of aberrant epithelial differentiation and hyperproliferation..Cell Death Differ2014;21:761-73 PMCID:PMC3978305

[30] Pellacani D,Frame FM,Berry PA,Stower MJ,Collins AT.Regulation of the stem cell marker CD133 is independent of promoter hypermethylation in human epithelial differentiation and cancer..Mol Cancer2011;10:94 PMCID:PMC3162587

[31] Peitzsch C,Hein L,Mabert K,Klink B,Wirth MP,Stakhovsky EA,Novotny V,Muders M,Frame FM,Baumann M.An epigenetic reprogramming strategy to resensitize radioresistant prostate cancer cells..Cancer Res2016;76:2637-51

[32] Adamson RE,Evans H,Schenk E,Birnie R,Dhawan A.In vitro primary cell culture as a physiologically relevant method for preclinical testing of human oncolytic adenovirus..Hum Gene Ther2012;23:218-30

[33] Schenk E,Kraaij R,Maitland NJ.Preclinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer..Hum Gene Ther Clin Dev2014;25:7-15

[34] Schenk E,Bangma CH,Barber C,Briggs S,Cheng WS,Dautzenberg IJ,Erbacher P,Frazier A,Hoeben R,Koppers-Lalic D,Kreppel F,Magnusson M,Neuberg P,Ogris M,Scaife M,Seymour L,Uil TG,Veldhoven-Zweistra JL,van Weerden W,Willemsen R.Clinical adenoviral gene therapy for prostate cancer..Hum Gene Ther2010;21:807-13

[35] Frew AJ,Bolden JE.Enhancing the apoptotic and therapeutic effects of HDAC inhibitors..Cancer Lett2009;280:125-33

[36] Zhao SG,Spratt DE,Yu M,Alshalalfa M,Tomlins SA,Dicker AP,Cooperberg MR,Karnes RJ,Schaeffer EM,Nguyen PL.Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis..Lancet Oncol2016;17:1612-20

[37] Yang L,Eustace A,Denley H,Alsner J,Harris AL,West CML.A gene signature for selecting benefit from hypoxia modification of radiotherapy for high risk bladder cancer patients..Clin Cancer Res2017;23:4761-8

[38] Birnie R,Roome C,Droop A,Berry PA,Lewis JL,Maitland NJ.Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions..Genome Biol2008;9:R83 PMCID:PMC2441469

[39] Kroon P,Stower MJ,Mann VM,Bhasin D,Li C,Maitland NJ.JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells..Cancer Res2013;73:5288-98

[40] Frame FM,Pellacani D,Walker HF,Collins AT.Development and limitations of lentivirus vectors as tools for tracking differentiation in prostate epithelial cells..Exp Cell Res2010;316:3161-71

[41] Swift SL,Maitland NJ.Altered expression of neurotensin receptors is associated with the differentiation state of prostate cancer..Cancer Res2010;70:347-56

[42] Lang SH,Fordham R.Modeling the prostate stem cell niche: an evaluation of stem cell survival and expansion in vitro..Stem Cells Dev2010;19:537-46 PMCID:PMC3158388

[43] Nappo G,Santer FR,Seed RI,Morrone G,Maitland NJ.The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling..Oncogenesis2017;6:e342 PMCID:PMC5523058

[44] Oldridge EE,Stower MJ,Mann VM,Pellacani D.Retinoic acid represses invasion and stem cell phenotype by induction of the metastasis suppressors RARRES1 and LXN..Oncogenesis2013;2:e45 PMCID:PMC3641360

[45] Rane JK,Maitland NJ.Advanced prostate cancer -- a case for adjuvant differentiation therapy..Nat Rev Urol2012;9:595-602